Equities Analysts Offer Predictions for CRSP FY2024 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at William Blair issued their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a research note issued to investors on Monday, December 9th. William Blair analyst S. Corwin expects that the company will earn ($4.66) per share for the year. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.17) per share. William Blair also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($0.74) EPS, Q1 2025 earnings at ($1.03) EPS, Q2 2025 earnings at ($0.97) EPS, Q3 2025 earnings at ($0.92) EPS, Q4 2025 earnings at ($0.38) EPS and FY2025 earnings at ($3.31) EPS.

A number of other research firms have also recently weighed in on CRSP. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Barclays lowered their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Chardan Capital reiterated a “buy” rating and issued a $94.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research note on Wednesday. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $77.93.

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $45.40 on Wednesday. The firm has a market capitalization of $3.88 billion, a price-to-earnings ratio of -16.04 and a beta of 1.62. The business has a fifty day moving average of $48.83 and a 200 day moving average of $51.29. CRISPR Therapeutics has a 1 year low of $43.42 and a 1 year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period in the prior year, the business posted ($1.41) earnings per share.

Hedge Funds Weigh In On CRISPR Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. SFE Investment Counsel grew its position in shares of CRISPR Therapeutics by 3.6% during the 2nd quarter. SFE Investment Counsel now owns 5,846 shares of the company’s stock worth $316,000 after buying an additional 203 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in CRISPR Therapeutics by 4.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock valued at $249,000 after buying an additional 211 shares in the last quarter. Boston Family Office LLC lifted its stake in CRISPR Therapeutics by 2.2% in the third quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock valued at $459,000 after buying an additional 213 shares in the last quarter. Bedell Frazier Investment Counselling LLC lifted its stake in CRISPR Therapeutics by 0.8% in the third quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock valued at $1,238,000 after buying an additional 218 shares in the last quarter. Finally, National Bank of Canada FI lifted its stake in CRISPR Therapeutics by 35.0% in the second quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after buying an additional 220 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

Insider Activity at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This represents a 1.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,382 shares of company stock valued at $2,744,179 over the last ninety days. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.